• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Moderate Pain - Pipeline Review, H2 2012 Product Image

Moderate Pain - Pipeline Review, H2 2012

  • Published: November 2012
  • 45 pages
  • Global Markets Direct

Moderate Pain – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Moderate Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Moderate Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Moderate Pain.
- A review of the Moderate Pain products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Moderate Pain Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Moderate Pain 7
Moderate Pain Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Moderate Pain Therapeutics – Products under Development by Companies 13
Companies Involved in Moderate Pain Therapeutics Development 14
Nektar Therapeutics 14
Elite Pharmaceuticals, Inc. 15
Atlantic Pharmaceuticals, Inc. 16
KemPharm, Inc. 17
TheraQuest Biosciences, LLC 18
Moderate Pain – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ELI-216 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Duexis - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NKTR-181 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NKTR-194 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
buprenorphine hydrochloride ER - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ATLP-0001 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
naproxen + famotidine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
hydromorphone hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Moderate Pain Therapeutics – Drug Profile Updates 36
Moderate Pain Therapeutics – Discontinued Products 40
Moderate Pain Therapeutics - Dormant Products 41
Moderate Pain – Product Development Milestones 42
Featured News & Press Releases 42
May 17, 2012: Janssen Presents Phase III Study Results Of NUCYNTA ER Extended-Release Tablets At 31st Annual Scientific Meeting Of American Pain Society 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Moderate Pain, H2 2012 7
Products under Development for Moderate Pain – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Nektar Therapeutics, H2 2012 14
Elite Pharmaceuticals, Inc., H2 2012 15
Atlantic Pharmaceuticals, Inc., H2 2012 16
KemPharm, Inc., H2 2012 17
TheraQuest Biosciences, LLC, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Moderate Pain Therapeutics – Drug Profile Updates 36
Moderate Pain Therapeutics – Discontinued Products 40
Moderate Pain Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Moderate Pain, H2 2012 7
Products under Development for Moderate Pain – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos